The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 26, 2010
Filed:
Jul. 23, 2007
Shekhar Viswanath, Vernon Hills, IL (US);
Larry Bartelt, Highland Park, IL (US);
Robert Leanna, Grayslake, IL (US);
Michael Rasmussen, Racine, WI (US);
Madhup Dhaon, Mundelein, IL (US);
Rodger Henry, Wildwood, IL (US);
Thomas Borchardt, Kenosha, WI (US);
Shuang Chen, Gurnee, IL (US);
Geoff Zhang, Libertyville, IL (US);
Shekhar Viswanath, Vernon Hills, IL (US);
Larry Bartelt, Highland Park, IL (US);
Robert Leanna, Grayslake, IL (US);
Michael Rasmussen, Racine, WI (US);
Madhup Dhaon, Mundelein, IL (US);
Rodger Henry, Wildwood, IL (US);
Thomas Borchardt, Kenosha, WI (US);
Shuang Chen, Gurnee, IL (US);
Geoff Zhang, Libertyville, IL (US);
Abbott Laboratories, Abbott Park, IL (US);
Abstract
A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.